Mission Statement

Our mission is to foster greater understanding among the general public, medical audiences and other key stakeholders, about what biotechnology is, where it has come from and its role in medicine, including its risks and benefits. This commitment drives everything we do. This is to be achieved through world-class on-line collections of historical sources, exhibitions, interactive experiences, films and learning programmmes.

Objectives

Our goal is to provide trusted and reliable educational resources targeting people at various ages ranging from school children through to university and those pursuing continuing professional development modules to facilitate better understandings about:

Public Benefit

Today biotechnology is one of the most important tools in medicine, helping in the diagnosis and treatment of disease. Yet, beyond genetic testing or embryonic stem cells which often grab media headlines, few understand the power of biotechnology and how it shapes everyday medical research, practice and treatment. The aim of BIOTECHMET is to provide educational resources on biotechnology and medicine free at point of access for the benefit of the general public, healthcare workers and other key stakeholders. No such resources are available to these audiences, all of whom are affected by the everyday application of biotechnology in medicine.

Projects

This charity aims to support the development of different educational resources for a variety of audiences. One of the first projects it is supporting is the website What is Biotechnology? Launched in February 2013 the website gets well over 1,000 page views a day and is on target to double this number within a year. It attracts visitors from around the world, including school children, policy makers, industry experts, scientists and financial investors. Many schools and universities have listed the site as a major teaching resource.

Trustees

James Christie

James holds the post of Project Director with responsibility for manufacturing at the Association of the British Pharmaceutical Industry (ABPI). At the ABPI James heads the implementation of work under the Medicines Manufacturing Industry Partnership. Prior to joining the ABPI James worked for Oxford BioMedica, as head of manufacturing and supply chain for over three years. While in this role he secured funding under the Advanced Manufacturing Supply Chain Initiative to implement a patient centric gene therapy supply chain. Prior to this he held senior management positions at GlaxoSmithKline, Celltech Group and Centocor BV.

Peter Gluckman BA, MSc, HonMFPH

Peter has held Board level and change agent positions within primary, secondary and specialist care, within mental health and led integration programmes for the NHS with social services and education. He also knows the charity and independent sector having worked with them on important regeneration activities and within the context of Local Strategic Partnerships. Most recent work includes leadership and support to assist in achieving Foundation Trust status and consultancy to support the DOH team dedicated to working with challenged NHS organisations. He was also responsible for planning and implementing the London component of the Health Protection Agency. He is an honorary member of the Faculty of Public Health.

Tara Hein-Phillips

Tara has over 15 years of experience in digital transformation, new product development, and commercial management. She is the managing director of Vestar Consulting, a consultancy focused on the intersection of education and technology. Tara works with corporate and education clients offering strategic direction, product design, new product development, implementation of learning systems and project oversight as these companies have made the shift from offline/classroom/print to digital.

Jenny Murray

Jenny has over 25 years of experience in the antibody and cell culture industry, working with her husband, David Murray, to offer the first commercially available monoclonal antibodies from Cesar Millstein's lab. Jenny was the Managing Director and founder of Seralab Ltd, a company producing cell culture sera and other biological material. Seralab was sold in July 2014 to BioreclamationIVT, a US supplier of biological material. Jenny is owner and Managing Director of Antibody Production Services Ltd, a company producing quality monoclonal antibodies and polyclonal antisera, contract filtration and production services. Jenny will take over as Chair of the Industry Serum Industry Association in June 2016 and is a member of the ISIA European Regulatory Affairs Team and SERA Education programme with a special interest in the regulatory issues surrounding the movement of animal by-products worldwide.

Russell Walters

Russell has a degree in biochemistry and is a qualified accountant. Until recently he was the Head of Operations in the Planning and Development Group at English Heritage. He is currently Chief Executive Officer for the St Olave's & St Saviour's Schools Foundation and Chair of the governors at Riverhead Infants School.

The Biotechnology and Medicine Education Trust (Biotechmet) is a registered charity with the Charity Commission. Registered Charity Number 1165469.